Enjoy complimentary customisation on priority with our Enterprise License!
The BCL-2 (b-cell lymphoma 2) inhibitors market is estimated to grow at a CAGR of 12.92% between 2022 and 2027. The size of the market is forecast to increase by USD 1,657.08 million. The growth of the market depends on serval factors, including the rising geriatric population, growing awareness about hematological malignancies, and high target affinity and specificity of BCL-2 inhibitors.
This report extensively covers market segmentation by product (combination therapy and monotherapy), type (diffuse large b-cell lymphoma (DLNCL), follicular lymphoma, chronic lymphocytic leukemia, and mantle cell lymphoma (MCL)), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
To learn more about this report, Download Report Sample
The reports categorize the global BCL-2 inhibitors market as a part of the global pharmaceuticals market within the overall healthcare industry. The parent global pharmaceuticals market covers products and companies engaged in R&D or production of generic drugs, non-generic drugs, and veterinary drugs. Our research report has extensively covered external factors influencing the parent market growth during the forecast period.
The rise in the geriatric population is notably driving the b-cell lymphoma 2 inhibitors market growth, although factors such as the availability of substitutes may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Key BCL-2 (B-cell Lymphoma 2) Inhibitors Market Driver
The rise in the geriatric population is one of the key drivers supporting the BCL-2 inhibitors market growth. According to the Centers for Disease Control and Prevention (CDC), the US geriatric population is expected to increase to 19.6% in 2030, while it was approximately 2.4% in 2000. The population of adults aged 80 years and above in the US was approximately 9.3 million in 2000, and it is expected to reach 19.5 million by 2030.
As the geriatric population is an important sub-group that is more likely to be affected by indications such as CLL/SLL and AML in comparison to the young adult population, the market is expected to witness an increase in the patient population. Thus, as the geriatric population has been increasing globally, the patient pool for indications such as CLL/SLL and AML is expected to grow, thereby contributing to the growth of the global BCL-2 inhibitors market growth during the forecast period.
Significant BCL-2 (B-cell Lymphoma 2) Inhibitors Market Trend
Growing approval of combination therapy is the key trend in the b-cell lymphoma 2 inhibitors market. The market growth is driven mainly by the label expansion of venetoclax combination therapy and the advantages of combination therapy. For instance, in 2021, the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for Venclexta (venetoclax) in combination with azacitidine.
Similarly, in March 2021, venetoclax in combination with azacitidine or LDAC was approved in Japan. Thus, the rising global acceptance of venetoclax combination therapy will drive market growth during the forecast period.
Major BCL-2 (B-cell Lymphoma 2) Inhibitors Market Challenge
The availability of substitutes is one of the factors hindering the b-cell lymphoma 2 inhibitors market growth. For instance, biologics have minimum to negligible adverse effects. Chemotherapy, radiation therapy, and surgery have a strong adoption in the treatment landscape. Meanwhile, leukapheresis is a procedure in which white blood cells, along with leukemia cells, are removed to ease normal circulation and prevent heart failure and respiratory problems before the chemotherapy drugs are administered. These substitutes aim to remove all cancerous cells, which largely renders these therapies remissive.
The curative nature of these alternatives, along with lesser side effects, render them popular substitutes for treatments, such as chemotherapy, including BCL-2 inhibitors. Thus, advances in and the availability of alternative therapies are expected to be among the major barriers to the growth of the global BCL-2 inhibitors market during the forecast period.
Key BCL-2 (B-cell Lymphoma 2) Inhibitors Market Customer Landscape
The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global BCL-2 (B-cell lymphoma 2) Inhibitors Market Customer Landscape
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc. - The company operates under one segment. Under this segment, the company conducts research and development, manufacturing, commercialization, and sale of innovative medicines and therapies to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. The company offers BCL-2 (B-cell lymphoma 2) inhibitor namely S55746 as its key offering.
The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
The market share growth of the combination therapy segment will be significant during the forecast period. Combination therapy was the largest segment of the global BCL-2 inhibitors market in 2021. The growth of this segment is mainly driven by the label expansion of venetoclax from monotherapy to combination therapy and the advantages of combination therapy over monotherapy. The combination therapy using venetoclax has high efficacy and tolerability compared with monotherapy.
Get a glance at the market contribution of various segments Request a PDF Sample
The combination therapy segment was valued at USD 980.92 million in 2017 and continued to grow until 2021. The segment of the BCL-2 inhibitors market is growing rapidly due to the increasing incidence of cancer, the availability of new drugs, and the high demand for effective cancer treatments, which, in turn, will contribute to the growth of the global BCL-2 inhibitors market during the forecast period.
For more insights on the market share of various regions Request PDF Sample now!
North America is estimated to contribute 55% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
The growth of the market in the region is driven by the recent approvals of venetoclax combinations in the US. For instance, in 2021, the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for Venclexta (venetoclax) in combination with azacitidine. This type of special regulatory designation encourages companies to expand drug development for other diseases as well. Venetoclax was jointly developed and commercialized by AbbVie and Roche in the US and by AbbVie outside the US. Moreover, in the US, approximately 10,000 people are diagnosed with myelodysplastic syndromes (MDS) every year, and therefore, there is a high unmet need for new treatment options. Vendors in the region are working on clinical trials to introduce new therapies in the region to meet the demand. For instance, Abbvie is working on a number of combination therapies that are currently in clinical trials, such as navitoclax in combination with ruxolitinib, which is in the phase 2 study. Thus, the expected approval of venetoclax combination therapy will drive market growth in the region during the forecast period.
In 2020, the outbreak of COVID-19 negatively impacted the growth of the regional BCL-2 inhibitors market in 2020. However, in 2021, several business and industrial activities resumed owing to large-scale vaccination drives, which increased the demand for BCL-2 inhibitors. Furthermore, the increasing demand for new and innovative drugs, the growing focus on personalized medicines, and the development of companion diagnostics are expected to increase the demand for BCL-2 inhibitors in the region. Such factors are anticipated to drive the growth of the regional market during the forecast period.
The report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
BCL-2 (B-cell Lymphoma 2) Inhibitors Market Scope |
|
Report Coverage |
Details |
Page number |
166 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 12.92% |
Market growth 2023-2027 |
USD 1,657.08 million |
Market structure |
Concentrated |
YoY growth 2022-2023(%) |
12.25 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 55% |
Key countries |
US, Canada, Germany, UK, and France |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Abcam plc, Amgen Inc., Ascentage Pharma Group International, AstraZeneca Plc, BeiGene Ltd., Bio Techne Corp., Biorbyt Ltd., Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Ipsen Pharma, Merck and Co. Inc., Novartis AG, Santa Cruz Biotechnology Inc., Seagen Inc., Servier, and AbbVie Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.